ClinicalTrials.Veeva

Menu

Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia

C

China Academy of Chinese Medical Sciences

Status

Unknown

Conditions

Primary Insomnia

Treatments

Drug: Chinese herbal Medicine
Other: the dummy of a Chinese Medicine prescription

Study type

Interventional

Funder types

Other

Identifiers

NCT01613183
PJZX-001
81072920 (Other Grant/Funding Number)

Details and patient eligibility

About

The objective of this study is to screen the effective core formulation in insomnia treatment with Chinese medicine with a double-blind, randomized, placebo-controlled trial.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • aged between 18 and 65 years,
  • meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) of insomnia,
  • Spiegel scale score is ≥ 18,
  • The informed consent must be obtained from patient

Exclusion criteria

  • total sleep time ≤ 2 hours,
  • secondary insomnia,
  • Self-rating Anxiety Scale (SAS) score ≥ 18,
  • Beck Depression Inventory (BDI) score ≥ 6,
  • having hypertension, diabetes, stroke, and coronary heart disease,
  • have drug abuse history,
  • pregnancy or preparing to pregnancy,
  • used immunotherapy or hormone therapy in past 1 years,
  • participating in another clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

2 participants in 2 patient groups, including a placebo group

Chinese Medicine group
Experimental group
Description:
Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
Treatment:
Drug: Chinese herbal Medicine
placebo group
Placebo Comparator group
Treatment:
Other: the dummy of a Chinese Medicine prescription

Trial contacts and locations

1

Loading...

Central trial contact

Peng Li, Bachelor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems